| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c06d114257182ee7efd4c696c5fdb836 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-324
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-323
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-32 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-567
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 |
| filingDate |
2002-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2007-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_112a62a4d70b83eee7f8697eefb5827a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb46b6e5e06395c2d8ef03f8d56114fd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_61943e64ae4cdc4a806c15622b6e48d2 |
| publicationDate |
2007-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-7189518-B2 |
| titleOfInvention |
Soluble CD40L(CD154) as a prognostic marker of atherosclerotic diseases |
| abstract |
This invention involves the new use of a diagnostic test to determine the risk of atherosclerotic diseases such as myocardial infarction and stroke, particularly among individuals with no signs or symptoms of current disease and among nonsmokers. Further, this invention involves the new use of a diagnostic test to assist physicians in determining which individuals at risk will preferentially benefit from certain treatments designed either to prevent first or recurrent myocardial infarctions and strokes, or to treat acute and chronic cardiovascular disorders. Methods for treatment also are described. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9057736-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8754197-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7932366-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008033153-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2302395-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9689880-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2016022654-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008058360-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007004800-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8048924-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007060552-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9682071-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011008805-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8314214-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019094581-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2924440-A2 |
| priorityDate |
2001-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |